Stocks
Cogent Biosciences, Inc.COGT
NASDAQHealthcareBiotechnology$33.41-3.76%
Price as of · delayed, not real-time
Focused on developing precision therapies for genetically defined diseases, this biotech firm specializes in kinase inhibitors targeting rare cancers and inflammatory conditions. Investors monitor its lead candidate, bezuclastinib, which shows promise in treating systemic mastocytosis and gastrointestinal stromal tumors.
Market Cap: $5.5B52W Range: $11.60-$43.73
Congressional Interest in Cogent Biosciences, Inc. (COGT)
1 member of Congress has disclosed 1 trade in Cogent Biosciences, Inc. (COGT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading COGT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K-$15K |